Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States

Documenti analoghi

• Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care
  di: Safraz A. Hamid, et al.
  Pubblicazione: (2025)
• Dacomitinib as a First‐Line Therapy for Advanced EGFR ‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study
  di: Ping‐Chih Hsu, et al.
  Pubblicazione: (2026)
• Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non‐Small‐Cell Lung Cancer Treated With Front‐Line Immunotherapy‐Based Therapies
  di: Mingjia Li, et al.
  Pubblicazione: (2025)
• Molecular Characteristics and Treatment Implications of TP53 Gain‐of‐Function Mutations in Non‐Small Cell Lung Cancer
  di: Zheng Zhao, et al.
  Pubblicazione: (2025)
• Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung Cancers
  di: Jinjing Tan, et al.
  Pubblicazione: (2025)